Drug Profile
Research programme: anti-CD11 antibody fragment - InNexus
Alternative Names: IXSCD 11aLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InNexus Biotechnology
- Class Antibodies
- Mechanism of Action CD11a antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in USA (Topical, Patch)
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in USA (Topical, Lotion)
- 06 Jan 2010 Early research in Psoriasis in USA (Topical)